Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
Phase 1: To establish the recommended Phase 2 dose for JNJ-40346527. Phase 2: To determine the overall response rate (complete response [CR] + partial response [PR]) in subjects with relapsed or refractory cHL.
Critère d'inclusion
- Subjects with Relapsed or Refractory Hodgkin’s Lymphoma